BRCA2 and breast cancer: In parallel, the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) international consortium (including members of COVAR), which is an initiative to evaluate risk and determine the clinical significance of unclassified BRCA1, BRCA2 and other breast cancer susceptibility genes variants, has conducted a collaborative study of known or potentially spliceogenic BRCA2 variants [31].